DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
Agency: Dept. of the Army -- USAMRAA
Assistance Listings: 12.420 -- Military Medical Research and Development
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.
Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.
Eligibility
Eligible applicants
Miscellaneous
- Unrestricted
Additional information
Grantor contact information
Description
eBRAP Help Desk
Documents
| File name | Description | Last updated |
|---|---|---|
| HT942526ALSRPTIA_GG.pdf | FY26 ALSRP TIA Program Announcement | May 4, 2026 01:51 PM UTC |
Link to additional information
--
Closing: September 30, 2026
Award
$10,080,000
Program Funding
12
Expected awards
$--
Award Minimum
$--
Award Maximum
Funding opportunity number:
HT942526ALSRPTIA
Cost sharing or matching requirement:
Funding instrument type:
Grant
Opportunity Category:
Discretionary
Opportunity Category Explanation:
Category of Funding Activity:
Science technology and other research and development
Category Explanation:
History
Version:
1
Posted date:
May 4, 2026
Archive date:
October 30, 2026
